HUM Stock Recent News
HUM LATEST HEADLINES
Bragar Eagel & Squire, P.C. Litigation Attorney Brandon Walker Encourages Investors Who Suffered Losses In Humana (HUM) To Contact Him Directly To Discuss Their Options
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening. Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage members nationwide beginning in August 2025. Humana, the fourth largest private insurer in the United States, has approximat.
Humana's Q2 earnings fall year over year on a declining membership base. Notably, 2025 adjusted EPS is currently forecasted at around $17.00, up from the earlier view of around $16.25.
Humana Inc. (NYSE:HUM ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Celeste Marie Mellet - Chief Financial Officer George Renaudin - President of Insurance James A. Rechtin - President, CEO & Director Lisa M.
U.S. equities were mixed at midday as the market responded to the U.S. economy growing more than expected in the second quarter while waiting for today's decision by the Federal Reserve on interest rates. The S&P 500 and Nasdaq gained, but the Dow Jones Industrial Average fell.
Humana (HUM) shares took off Wednesday when the health insurer boosted its guidance as it sees fewer losses of Medicare Advantage customers than previously thought.
Although the revenue and EPS for Humana (HUM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
As the healthcare landscape evolves with new legislation and shifting demographics, Humana Inc. HUM is adapting to these changes through strategic adjustments. This adaptability is reflected in their second-quarter earnings report, which exceeded analysts' expectations despite a decline in adjusted EPS compared to last year.
Humana (HUM) came out with quarterly earnings of $6.27 per share, missing the Zacks Consensus Estimate of $6.32 per share. This compares to earnings of $6.96 per share a year ago.